Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy

Posted on November 24, 2015 by admin

by Stacey B. Trooskin, Helen Reynolds, and Jay R. Kostman
Clin Infect Dis 2015 61: 1825-1830

6 pp. 188 kB
http://cid.oxfordjournals.org/content/61/12/1825.full.pdf+html12.cover

Several breakthrough hepatitis C drugs received Food and Drug Administration approval in 2014, with cure rates exceeding 90%. These drugs are being rationed, due to costs. The authors propose an AIDS Drug Assistance Program analogue and cost-control mechanisms to facilitate treatment.

(Visited 62 times, 1 visits today)

Related posts:

  1. The Negative Impact of the War on Drugs on Public Health: The Hidden Hepatitis C Epidemic
  2. The Negative Impact of the War on Drugs on Public Health: The Hidden Hepatitis C Epidemic
  3. Global response to hepatitis C hangs on access to new oral drugs
  4. Access to hepatitis C medicines: Improving access to essential innovative treatments
  5. How Much? A Battle Over the Cost of the New Hepatitis C Drugs
This entry was posted in Essential Medicines, General, Other Infectious Diseases. Bookmark the permalink.